Inhibition of Both EGFR and IGF1R Sensitized Prostate Cancer Cells to Radiation by Synergistic Suppression of DNA Homologous Recombination Repair

Yong Wang1*, Jian Lin Yuan2*, Yun Tao Zhang2*, Jian Jun Ma1, Peng Xu2, Chang Hong Shi2*, Wei Zhang1, Yu Mei Li1, Qiang Fu1, Guang Feng Zhu1, Wei Xue1, Yong Hua Lei1, Jing Yu Gao1, Juan Ying Wang1, Chen Shao2*, Cheng Gang Yi5*, He Wang1*

1 Department of Urology, Tangdu Hospital, Fourth Military Medical University, Xi’an, Shaan’xi Province, P.R. China, 2 Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi’an, Shaan’xi Province, P.R. China, 3 Department of Medicine and Training, Tangdu Hospital, Fourth Military Medical University, Xi’an, Shaan’xi Province, P.R. China, 4 Department of Experimental Animals, Fourth Military Medical University, Xi’an, Shaan’xi Province, P.R. China, 5 Department of Plastic Surgery, Xijing Hospital, Fourth Military Medical University, Xi’an, Shaan’xi Province, P.R. China

Abstract

Reduced sensitivity of prostate cancer (PC) cells to radiation therapy poses a significant challenge in the clinic. Activation of epidermal growth factor receptor (EGFR), type 1 insulin-like growth factor receptor (IGF1R), and crosstalk between these two signaling pathways have been implicated in the development of radiation resistance in PC. This study assessed the effects of targeting both receptors on the regulation of radio-sensitivity in PC cells. Specific inhibitors of EGFR and IGF1R, Erlotinib and AG1024, as well as siRNA targeting EGFR and IGF1R, were used to sensitize PC cells. Our results showed that co-inhibiting both receptors significantly dampened cellular growth and DNA damage repair, and increased radio-sensitivity in PC cells. These effects were carried out through synergistic inhibition of homologous recombination-directed DNA repair (HRR), but not via inhibition of non-homologous end joining (NHEJ). Furthermore, the compromised HRR capacity was caused by reduced phosphorylation of insulin receptor substrate 1 (IRS1) and its subsequent interaction with Rad51. The synergistic effect of the EGFR and IGF1R inhibitors was also confirmed in nude mouse xenograft assay. This is the first study testing co-inhibiting EGFR and IGF1R signaling in the context of radio-sensitivity in PC and it may provide a promising adjuvant therapeutic approach to improve the outcome of PC patients to radiation treatment.

Introduction

Prostate cancer (PC) is the most common malignancy and the second leading cause of cancer-related deaths among male patients [1]. During cancer progression, the initial growth of PC cells is androgen-dependent, and these cells undergo apoptosis upon androgen depletion. As a consequence, androgen ablation was considered the standard treatment for PC for over 30 years [2]. Many patients eventually developed a hormone-refractory disease due to the growth of androgen-refractory cancer cells, which leads to failure of androgen ablation therapy and leaves patients with fewer therapeutic options [3,4]. Combination of definitive local therapies, such as radical prostatectomy together with adjuvant radiotherapy, has been demonstrated to improve the survival of PC patients [5,6]. However, such therapy is challenged by the emergence of resistance in tumor cells. It is, therefore, of paramount importance to develop novel therapeutic strategies to overcome radioresistance and improve radio-sensitivity by targeting molecular machineries in androgen-independent PC cells.

Epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor (IGF1R), two most important tyrosine kinase receptors, play critical roles in cancer development and progression through the regulation on cell proliferation, apoptosis, anchorage-independent growth, invasion, angiogenesis, cancer immunity and resistance to chemo- and/or radiotherapy [7]. These two receptors are frequently overexpressed in a variety of human cancers including PC [8,9,10], and therefore could be used as candidates for targeted cancer therapy. Indeed, inhibitors of EGFR and another EGFR family member Her2, including Erlotinib, Lapatinib, Cetuximab, and Gefitinib, are the most successful options in current clinical treatment of different human cancers, As expected however, the development of de novo resistance has been observed in clinic after long-term use of these medicines, suggesting the existence of bypass mechanisms within tumor cells [11]. Mechanistic studies on the cellular and molecular events revealed that extensive crosstalk between EGFR and IGF1R signaling occurs at multiple levels, and that blockade of EGFR signaling leads to enhanced responses to the IGF1R ligand,
IGF [12,13]. These data imply that targeting both receptors at the same time could provide better efficacy in cancer treatment and overcome tumor resistance to an individual inhibitor, while improving the sensitivity of individual inhibitors to cancer therapy. Consistently, studies have shown that dual targeting of both receptors blocks their reciprocal hyperphosphorylation, inhibits the proliferation and induces apoptosis in multiple cancer cells including PC and colorectal cancer [14,15].

In this study, we assessed the effects of targeting both EGFR and IGF1R signaling in the responses of PC cells to γ-irradiation. Our data demonstrated the potency of targeting both pathways in modulating the behaviors of PC cells following radiotherapy and revealed the underlying mechanisms. This is a seminal study that further justifies the combinatorial use of inhibitors for EGFR and IGF1R pathways in the treatment of PC.

Materials and Methods

Cell culture and treatment

The human androgen-independent PC cells DU145, PC3, ARCaP4, and ARCaP4 and human normal prostate epithelium cell line PrEC were purchased from American Type Culture Collection (Manassas, VA, USA). The R503 was from the Experimental Animal Center of the Fourth Military Medical University. The cells were treated with dimethyl sulfoxide (DMSO, as the vehicle control), 10 µM Erlotinib (EGFR inhibitor, Eton Bioscience, San Diego, CA) and/or 10 µM AG1024 (IGF1R inhibitor, Santa Cruz Biotechnologies, Santa Cruz, CA) (as experimental groups) for 1 h. Cells were irradiated as described by Liu et al [16]. In some experiments, the cells were also transfected with IRS1 or non-silencing control (NSC) siRNAs (50 nM, Invitrogen, Shanghai, China) according to manufacturer’s protocol.

To establish irradiation-tolerant sublines, PC cells were irradiated at 2 Gy per day, 5 days a week in a gate irradiation-alone setting. Our data demonstrated the potency of targeting both pathways in modulating the behaviors of PC cells following radiotherapy and revealed the underlying mechanisms. This is a seminal study that further justifies the combinatorial use of inhibitors for EGFR and IGF1R pathways in the treatment of PC.

Clonogenic assay

The synergistic colony formation following the combined treatment with of EGFR and IGF1 inhibitors and irradiation was investigated by monolayer clonogenic assays. Cells were serum-starved overnight. Five thousand cells were seeded into 10-cm-diameter tissue culture dishes with 10-mL medium. The cells were treated with AG1024 or Erlotinib for 1 h and irradiated at indicated dosage after they had adhered to the dishes. Colony formation was determined with crystal violet staining by using a Coulter particle counter on day 10 after cell seeding. Surviving fraction was defined as the cloning efficiency of the treated cells divided by that of the control cells. Experiments were repeated three times.

Flow cytometry assay

To analyze cell apoptosis, cells (1×10^6/well) were plated onto 6-well plates. After 24 h, cells were serum starved for 24 h, and then treated with either AG1024 or Erlotinib for 1 h. Cells were then irradiated at the dosage of 2 Gy. At 4 h after irradiation, the cells were stained with propidium iodide solution (0.2 mg of RNase A, 0.02 mg PI, and 1 mL Triton X-100). The DNA content in different cell-cycle phases was determined by FACS flow cytometer (BD Biosciences, San Jose, CA). To detect apoptotic rate in treated cells, the cells were stained with Annexin V and PI and then subjected to flow cytometry as described [16]. The Annexin V-positive and PI-negative cells undergoing early apoptosis were counted as apoptotic cells. All experiments were conducted in triplicates and data shown are representative of three independent experiments.

Protein extraction and Western blotting

Different groups of cells were lysed with 1% SDS lysis buffer (Beyotime Inc., Beijing, China). For nuclear protein extraction, the cells were washed with hypotonic lysis buffer (Teknova, Beijing, China), and lysed in the cell douncer (Wheaton Ltd, Milville, NJ). The nuclear components were then separated from cytosolic extracts by centrifugation, followed by lysis in RIPA buffer (Fierce Inc., Beijing, China).

Immunoprecipitation and Western-blot assay were performed as described as described by Liu et al [17]. The following antibodies were from Cell Signaling: anti-γH2AX, anti-IRS1, anti-phospho IR-S1(pY612), anti-IGF1R, anti-phospho EGFR, anti-EGFR, anti-phospho EGFR(Y1068), anti-β-tubulin, anti-ERK, anti-phospho-ERK, anti-AKT, anti-phospho AKT(S473), anti-DNA-PK, anti-Ku70, anti-Ku80, and anti-XRCC4. The anti-Lamin antibody was from Abnova (Shanghai, China). The anti-HP-1α antibody was from Millipore (Shanghai, China). β-tubulin, Lamin and HP-1α were used as loading controls.

Immunofluorescence

The γH2AX and Rad51 foci formation was investigated according to Barber et al [18]. For immunofluorescence staining for γH2AX and Rad51, cells were fixed in 1% paraformaldehyde for 10 min at room temperature followed by 70% ethanol for 10 min at room temperature. After wash with PBS containing 0.1% Triton for 10 min, cells were permeabilized with 0.5% Triton in PBS for 10 min at room temperature. After three washes in PBS, cells were blocked with 5% bovine serum albumin (BSA) in PBS for 60 min. Then anti-γH2AX (Treviron, Gaithersburg, MD, 1:2000) or anti-Rad51 antibody (Oncogene research, 1:300) was added in 5% BSA in PBS and incubated with cells at 4°C overnight with gentle shaking. After four washes in PBS, cells were incubated in the dark with a FITC-labeled secondary antibody in 5% BSA at a dilution of 1:2000 for γH2AX and 1:200 for anti-Rad51 detection for 1 h at room temperature. Following four more washes in PBS, the nuclei were stained in the dark with 4′,6-diamidino-2-phenylindole (DAPI) (1 µg/mL, Invitrogen) in PBS for 5 min, and coverslips were mounted with Fluoromount G (Southern Biotech., Birmingham, AL). Slides were examined on a Leica fluorescence microscope, with images captured by a CCD camera and imported into the Advanced SPOT Image analysis software (SPOT Imaging Solutions, Sterling Heights, MI). For each treatment condition, the γH2AX or Rad51 signals were determined in at least 50 cells. All observations were validated from at least three independent experiments.

Assays for HR-directed DNA repair (HRR) and the non-homologous end joining (NHEJ)

The quantitative in vitro homologous recombination (HR) assay was performed using the pDR-GFP recombination reporter system [19]. Briefly, the pDR-GFP plasmid expressing two nonfunctional GFP genes was stably transfected into DU145 cells. A second plasmid encoding the restriction enzyme I Sec-I and a third plasmid expressing red fluorescent protein (RFP) with a mitochondrial localization signal to indicate transfection efficiency.
were transiently transfected into DU145 cells containing the pDR-GFP plasmid. When I-SceI was expressed, it produced DNA double-strand breaks (DSBs) within the SceGFP fragment and stimulated HRR to restore intact GFP gene. DNA repair by HRR was evaluated by counting cells with both nuclear GFP signal and mitochondrial RFP signal vs. all positively transfected cells, that is, ratio of cells with both red and green signals to those with only red signals.

The cell-free NHEJ assay was performed as described previously [20] with nuclear extracts from 1×10^7 DU145 cells.

**In vivo tumor radiation therapy**

The animal experiments were approved by the Ethnic Committee of the Fourth Military Medical University (Xi’an, China). 5×10^6 DU145 cells were pre-mixed with Matrigel (BD Biosciences) for subcutaneous injection into the flank of 10-week-old female nude mice. Twenty-two days later (Day 0), the mice were randomly divided into 5 groups, 5 mice per group, based on the treatments they would receive: i.e., control group received no treatments; IR group received γ-irradiation of different dosages on days 3, 6, 8, and 10, respectively; IR+Erlotinib group received γ-irradiation as the irradiation group, plus 100 mg/kg/d of oral Erlotinib for 10 days; IR+AG1024 group received γ-irradiation, plus 100 mg/kg/d of oral AG1024 for 10 days; IR+Erlotinib+AG1024 received γ-irradiation, plus 100 mg/kg/d both drugs for 10 days. The tumor volume (V) was monitored every three days for seven weeks by measuring the length (L) and width (W), and calculated as V=0.5×L×W^2. The result was expressed as proliferation index (PI, PI=V treatment/V control).

**Statistical analysis**

The effect of Erlotinib and AG1024 on inhibition of cell proliferation, xenograft growth, clonogenic survival, and caspase activation was analyzed statistically using an unpaired two-tailed Student’s t test. All quantitative data were presented as mean ± SD from at least three independent experiments for *in vitro* experiments or from all animals within the group for *in vivo* experiments. P value of ≤0.05 was considered statistically significant. * and ** was labeled for P<0.05 and P<0.01 respectively, as compared to the control cells.

doi:10.1371/journal.pone.0068784.g001
Results

Reduction of tumor cell viability and induction of apoptosis by targeting of EGFR and/or IGF1R before irradiation treatment

In this study, we first assessed the induced sensitivity of different cancer cells to radiation in vitro. We grew and treated different cancer cell lines with Erlotinib (10 μM) and/or AG1024 (10 μM) for 1 h and then irradiated them with 2 Gy. Our data showed that tumor cell viability was significantly reduced and tumor cell apoptosis enhanced by irradiation following inhibition of both EGFR and IGF1R, as compared to irradiation treatment alone or irradiation plus blocking of either receptor (Figure 1A, B). Specifically, when compared to the vehicle-treated control cells, either AG1024 or Erlotinib significantly reduced tumor cell viability in epithelial PC cell lines (P < 0.05), yet the most robust growth-inhibitory effect by irradiation was achieved with simultaneous application of both inhibitors (P < 0.05, as compared to AG1024 or Erlotinib treatment in DU145, PC3 and ARCaPc cells) (Figure 1A). In contrast, AG1024 or and Erlotinib could not radio-sensitize normal prostate epithelium cell line PrEC (Figure 1A). Our data also showed that in both DU145 and PC3 cells, AG1024 significantly reduced the phosphorylation of IGF1R, whereas Erlotinib dramatically inhibited the phosphorylation of EGFR, and neither showing cross-activity on the other receptor, indicating that both inhibitors function potently and specifically (Figure S1).

Besides epithelial PC cells, we also assessed the effects of targeting both EGFR and IGF1R signaling in the radiosensitization response of mesenchymal-like PC cells. For this purpose, we used ARCaPc cells, the mesenchymal counterpart of ARCaPc developed by Graham et al [21]. Both cell lines exhibit minimal expression of androgen receptor [22]. Consistent with previous findings by Buck et al [14], combined treatment with EGFR and IGF1R inhibitors could not synergistically inhibit mesenchymal cell growth in response to irradiation, as it did for epithelial growth (Figure 1A).

To avoid the non-specific effects associated with small molecular inhibitors, we also repeated the experiment in Figure 1A using siRNA specific for EGFR and IGF1R (Figure 1B). As shown in Figure S2, both siRNA worked efficiently in knocking down IGF1R and EGFR, respectively. With single or dual knockdown of EGFR and/or IGF1R by siRNA, we obtained similar results as in Figure 1A (Figure 1B).

Next, we characterized the potential apoptotic effects of these two inhibitors using flow cytometry assay. As shown in Figure 1C, DU145, PC3 and ARCaPc cells showed enhanced radiosensitivity following increasing doses of AG1024 and/or Erlotinib, while ARCaPc was only sensitive to AG1024, but not to Erlotinib. Combined treatment with Erlotinib and AG1024 synergistically radio-sensitize DU145, PC3 and ARCaPc cells, but not ARCaPc cells. When comparing DU145 cells to PC3 cells, we found that the former are more sensitive to Erlotinib than the latter, given that 10 μM Erlotinib induced a robust apoptotic response over 1 μM Erlotinib in DU145 cells, while not much increase in apoptosis was observed in PC3 cells by the same dosages of Erlotinib. Similar results were also achieved with siRNA targeting EGFR and/or IGF1R (Figure 1D).

Enhancement of radio-sensitivity by EGFR and IGF1R inhibitors through impairment of DNA DSB repair

To understand the molecular mechanisms underlying enhanced radio-sensitivity of cancer cells in response to AG1024 and/or Erlotinib treatment, we determined the capacity of DNA double-strand break (DSB) in DU145 and PC3 cells, since DSB exerts the most lethal effect on cells induced by γ-irradiation. By monitoring the level of histone protein H2AX phosphorylation on the C-terminal serine 139 residue, also known as γH2AX, a well-known and sensitive DNA damage marker, we demonstrated that there was a rapid and robust phosphorylation of H2AX at 1 h after irradiation in both vehicle-treated control DU145 and PC3 cells (Figure 2A), which quickly declined at 4 h, and returned to the basal level at 24 h, implying the accomplishment of DSB repair. In contrast, tumor cells pre-treated with AG1024, Erlotinib, or both showed a delayed H2AX phosphorylation peak at 4 hour, and continuous H2AX phosphorylation till 24 h after irradiation, suggesting impairment of DSB repair after AG1024 and Erlotinib treatment (Figure 2A, B). Moreover, there was a significant difference between AG1024+Erlotinib group and AG1024 or Erlotinib group (5 and 10 Gy, P < 0.01), indicating an additive effect of co-inhibition on the DSB repair process (Figure 2B).

Effects of EGFR and IGF1R inhibitors on impairment of DSB repair through inhibition of HRR, but not of NHEJ

To differentiate whether the impaired DSB repair was due to a defect in HRR or NHEJ, the two major pathways for DSB repair, we quantitatively assessed HRR using the pDR-GFP recombinase reporter system and examined NHEJ using an in vitro cell-free assay [20]. As shown in Figure 2C, for DU145 cells, combined treatment with AG1024 and Erlotinib potently reduced HRR level when compared to the vehicle control or each agent alone (P < 0.05). In contrast, the nuclear extract treated with individual inhibitor or both were unable to alter the in vitro ligation of pBluescript KS (+), when compared to the nuclear extract from vehicle control cells (Figure 2D). For this analysis, the nuclear extract from R503 cells was used as the positive control, as demonstrated by Yang et al [23]. In addition, expression of NHEJ-related DNA repair proteins, including DNA-PK, Ku70, Ku80 and XRCC4, were not affected by AG1024, Erlotinib or both in DU145 cells (Figure 2E), suggesting that inhibition of these two signaling pathways did not impair NHEJ-initiated DNA DSB repair, one of the most common forms of DSB repair in mammalian cells.

Suppression of signal crosstalk at multiple levels by inhibiting both EGFR and IGF1R

Previous studies revealed extensive crosstalk between EGFR and IGF1R signaling pathway at multiple levels [14]. Our data above have demonstrated that co-inhibition of EGFR and IGF1R could additively radio-sensitize PC cells through the impairment of HRR DSB repair. To further investigate how the interaction between the two receptors affects DSB repair, we performed immunoprecipitation-Western-blot to examine the physical interaction between EGFR and IGF1R in DU145 and PC3 cells following γ-irradiation. Our data showed that without irradiation, these two receptors interacted with each other in both tumor cell lines and that this association was not significantly altered at 24 h after irradiation (Figure 3A). Moreover, we determined the downstream signal transduction of one receptor in response to the ligand of the other receptor. As shown in Figure 3B, for DU145 and PC3 cells, phosphorylation of EGFR was increased in a dose-dependent manner to IGF-I treatment in both cells but was significantly reduced upon co-treatment with the EGFR inhibitor, Erlotinib. Similarly, phosphorylation of IRS1, the major IGF1R signaling molecule, was enhanced after treatment with increasing concentrations of EGF, but was inhibited after addition of AG1024 (Figure 3C). In addition, we found that the ligand for
each receptor, i.e., IGF-I and EGF, was sufficient to activate these target genes in DU145 and PC3 cells. However, the most robust activation was achieved with co-treatment with both IGF-I and EGF, whereas blockage of these receptors signaling with either AG1024 or Erlotinib was able to reduce activation of these target genes, but the most potent reduction was observed in DU145 and PC3 cells pre-treated with both inhibitors (Figure 3D). These data suggest that co-treatment with EGFR and IGF1R inhibitors was able to suppress their crosstalk and in turn block their downstream signaling, including PI3K/AKT pathway and MAPK pathway.

Effects of EGFR and IGF1R inhibitors on suppression of IRS1/Rad51-mediated homologous recombination

Our current data on AG1024 and Erlotinib regulating IRS1 phosphorylation/activation implicated the potential involvement of IRS1/Rad51-mediated HRR in response to γ-irradiation in PC cells, as previous study also indicated [24]. Indeed, our data showed that IRS1 phosphorylation was induced by γ-irradiation with peak activation achieved at 4 h after γ-irradiation in DU145 and PC3 cells, while the peak of IRS1 phosphorylation was delayed to 8 h after γ-irradiation following treatment with AG1024 or Erlotinib alone. In contrast, co-treatment with both AG1024 and Erlotinib significantly reduced IRS1 activation not...
Only at the basal level (0 h post-irradiation) but also at all time points up to 24 h after irradiation (Figure 4A).

Next, we determined the physical interaction between IRS1 and Rad51 in the nuclear fraction of cells followed -irradiation using immunoprecipitation. As shown in Figure 4B, treatment with vehicle, AG1024, Erlotinib or AG1024 plus Erlotinib did not significantly change levels of IRS1 or Rad51 protein, whereas levels of IRS1-associated with Rad51 were dramatically reduced in cells treated with AG1024 plus Erlotinib, which is consistent with the significantly reduced level of phospho-IRS1 in these cells. These data demonstrated that AG1024 plus Erlotinib treatment suppressed IRS1 interaction with Rad51, indicating EGFR and IGF1R co-inhibition could inhibit DNA double strand break repair by inhibition of HRR.

In addition, we also determined the subcellular localization of Rad51 that forms nuclear foci at sites of DNA lesions. Our data showed that approximately 15% of vehicle-treated control cells were positive for Rad51 nuclear foci after exposure to -irradiation. The percentage of cells with positive foci was significantly reduced when the cells were pre-treated with either AG1024 or Erlotinib (P<0.05), and was more robustly reduced in those co-treated with AG1024 plus Erlotinib cells (P<0.01, Figure 4C). The positivity of Rad51 nuclear foci was associated with the levels of IRS1 phosphorylation. The positive relationship

Figure 3. Effects of EGFR and IGF1R inhibitors on crosstalk between EGFR and IGF1R signaling pathways at multiple levels. A, Immunoprecipitation detecting EGFR/IGF1R interaction. DU145 and PC3 cells were irradiated at the dose of 2 Gy. Then cellular proteins were extracted, and subjected to immunoprecipitation assay detecting EGFR and IGF1R interaction. B, IGF-I activates EGFR in DU145 and PC3 cells. Cells were serum-starved overnight, and then subjected to IGF-I stimulation for 30 min. EGFR phosphorylation was detected by Western blot. C, EGF activates IRS1, the key factor of IGF1R signal pathway in DU145 and PC3 cells. Cells were serum-starved overnight, and then subjected to EGF stimulation for 30 min. IRS1 phosphorylation was detected by Western blot. D, MAPK or AKT activation after EGFR and IGF1R simulation of inhibition. DU145 and PC3 cells were treated with or without AG1024 (10 μM), Erlotinib (10 μM), AG1024 plus Erlotinib; IGF (50 ng/mL), EGF (50 ng/mL), or EGF plus IGF for 30 min. Then ERK1/2 expression and phosphorylation, AKT expression and phosphorylation, IRS1 expression and phosphorylation was determined by Western blotting. β-tubulin was used as a loading control.

doi:10.1371/journal.pone.0068784.g003
between IRS1 activation and positivity of Rad51 nuclear foci was further supported by targeting IRS1 using IRS1 siRNA. When compared to mock-transfected cells or those transfected with non-silencing control siRNA (NSC siRNA), IRS1 siRNA significantly reduced the total IRS1, IRS1 phosphorylation, and the number of positive cells with Rad51 nuclei foci ($P < 0.05$, Figure 4C). To further characterize the regulation of Rad51 nuclear foci formation, we pre-treated cancer cells with EGFR inhibitor Erlotinib, PI3K inhibitor LY294004, or ERK inhibitor PD98059 and found that only pre-treatment with Erlotinib led to significant reduction of Rad51-positive nuclear foci ($P < 0.05$, Figure 4D), implying that regulation of Rad51-mediated HRR depends on upstream signaling molecule(s) such as IRS1, rather than downstream ones, such as PI3K/AKT or ERK.

**Effects of EGFR and IGF1R inhibitors on sensitization of cancer cells to radiotherapy in vivo**

Our results so far demonstrated the effects of these EGFR and IGF1R inhibitors on PC cells with or without $\gamma$-irradiation in vitro. Next, we further determined their in vivo effects using the nude mouse xenografts model. We injected parental DU145 cells as well as irradiation-resistant sublines DU145-IIRR into nude mice. As shown in Figure 5A, tumors derived from DU145-IIRR were significantly more resistant to $\gamma$-irradiation than tumors derived from the parental DU145. However, this resistance was diminished after treatment with either Erlotinib or AG1024, or both in a time-dependent manner. As shown in the left panel of Figure 5B, $\gamma$-irradiation significantly reduced in vivo tumor growth of parental DU145 ($P < 0.05$, as compared to the control mice), which was further reduced by treatment with AG1024 or Erlotinib ($P < 0.05$, as compared to $\gamma$-irradiation mice), and by co-treatment with AG1024 plus Erlotinib ($P < 0.05$, as compared to $\gamma$-irradiation plus AG1024 or $\gamma$-irradiation plus Erlotinib mice). Although tumor growth was not dramatically affected by irradiation over time with DU145-IIRS cell injections, treatment with AG1024, Erlotinib, or both sensitized the tumors to $\gamma$-irradiation. Combined treatment with both inhibitors significantly inhibited tumor growth, comparing with any one of these inhibitor treatment, indicating the synergistic growth inhibitive effect.

**Discussion**

In this study, we investigated whether co-targeting of EGFR and IGF1R could sensitize PC cells to $\gamma$-irradiation. Our current data provide evidence that crosstalk between EGFR and IGF1R occurs not only at the cell surface via the receptor interaction, but also through their crosstalk, and thus targeting both pathways interferes HRR of DSB repair by modulating IRS1 and Rad51 interaction, resulting in radio-sensitization of PC cells.
Radiotherapy induces multiple types of damage in genomic DNA, including single-strand breaks (SSB), DSB, base alterations, DNA-DNA, and DNA-protein crosslinks. Without proper DNA repair capacity, cells undergo apoptosis, mitotic catastrophe, autophagy, cellular senescence, or even carcinogenesis [25]. However, in tumor cells after radiation therapy, enhanced DNA repair capacity such as HRR or NHEJ leads to resistance to radiotherapy. HRR is a template-driven and thus error-free DNA repair mechanism that involves many proteins including Rad51, p53, BRCA2, BLM, and RPA. NHEJ is a more error-prone mechanism that operates with DNA repair proteins such as Ku70/80, XRCC4, XRCC1, DNA-PK, and XLF [25]. In the current study, we showed that inhibition of both EGFR and IGF1R was able to suppress HRR repair of damaged DNA after γ-irradiation, but not NHEJ repair. This explains why the combination of these two inhibitors could synergistically inhibit HRR, but only showing additive effect on DSB repair inhibition, consistent with previous studies that NHEJ is the main mechanism of DSB repair [26].

Indeed, studies over the past decade have suggested several mechanisms of regulation between radiation-induced EGFR and IGF1R signaling and DSB repair. Both signaling pathways including the downstream signaling cascades are activated in response to ionizing radiation [27]. Upon their activation, the PI3K-AKT and Ras-MAPK pathways present specific activity toward resistance to chemo- and radio-therapy, in addition to their regulatory capability on cell viability, apoptosis and cell proliferation [28,29]: The Ras-MAPK pathway stimulates production of EGFR ligand and in turn activates EGFR in an autocrine manner, while PI3K-AKT pathway directly activates the catalytic subunit of DNA-PK, the essential component for NHEJ machinery. The nuclei-localized EGFR protein following activation will facilitate nuclear localization of DNA-PK and therefore, promote NHEJ in addition to transcriptional regulation of XRCC1 and BER expression. These studies suggest a preferential link between EGFR signaling and NHEJ-mediated DNA repair. However, NHEJ was not affected by EGFR and IGF1R inhibition.

Figure 5. In vivo effects of EGFR and IGF1R inhibitors in sensitivity of prostate cancer to radiotherapy. A, Dose-proliferation relation of nude mouse xenograft growth. Prostate cancer DU145 and irradiation-resistant DU145IIRR cells were subcutaneously injected into nude mice to form xenograft tumors and followed by indicated treatments and γ-irradiation. At day 40 after treatment, the tumor growth in different mice was presented as proliferation index. The data were presented as mean ± SD from three independent experiments. *P < 0.05, **P < 0.01, as compared to the control cells. B, Time-proliferation relation of nude mouse xenograft growth. At different time points after treatment, the tumor growth in different groups was presented as the proliferation index. C, Schematic diagram illustrating co-inhibition of EGFR and IGF1R sensitizes prostate cancer to radiotherapy via inhibition of HRR DNA damage repair. EGFR and IGF1R are able to directly interact with each other to activate multiple downstream genes, such as IRS1, ERK, and AKT. Upon γ-irradiation, this interaction was not affected, while facilitating NHEJ and IRS1/Rad51-mediated HRR for DNA double-strand break repair. Simultaneously blockage of EGFR and IGF1R gene pathways disrupts their crosstalk on multiple levels; for example, suppression of EGFR/IGF1R interaction, attenuation of IRS1 phosphorylation and impairment of IRS1/Rad51-mediated HRR. However, NHEJ was not affected by EGFR and IGF1R inhibition.

doi:10.1371/journal.pone.0068784.g005
PC3 to IGF1R and EGFR inhibitors, which may result from the different PTEN status in these two cell lines, since DU145 is positive forWhile PC3, negative for PTEN.

Furthermore, in this study, we demonstrated mechanisms of crosstalk between EGFR and IGF1R signaling pathways at multiple levels. DU145 and PC3 cells showed that these two receptors physically interact, and the activation of one receptor led to stimulation of the other. Moreover, several downstream targets, including IRS1, AKT and ERK were synergistically activated by co-stimulation of both receptors (Fig. 3D). These data revealed a novel strategy by using inhibitors of both receptors to effectively treat PC and sensitize cells to γ-irradiation therapy. However, further studies will be required before this can be translated into clinical practice. Up to now, the main method of to treat PC is hormone therapy. Prostate cancers are mostly androgen-sensitive in the beginning, and inevitably transform to androgen-insensitive and become androgen-refractory as PC progresses. Therefore, PC patients differ in androgen sensitivity. In this research, we used androgen-independent PC cell lines in this research. Whether our findings could be extended to androgen-sensitive or androgen-refractory PC needs to be further investigated.

In summary, we provide the first experimental evidence that in androgen-independent PC cells, crosstalk between EGFR and IGF1R contributes to radiation-induced DSB repair through the suppression of HRR via IRS1/Rad51 signal pathway. Even though other DNA repair mechanisms, such as those for DNA-SSB, altered DNA bases, and DNA-DNA or DNA-protein crosslink, may function following radiation-induced DNA lesions, targeting both EGFR and IGF1R activities may provide a novel approach for improving the efficacy of anti-PC radiotherapy.

**References**

1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277–300.
2. Ruizeveld de Winter JA, Jansen PJ, Steddens HM, Verleun-Mooijman MC, Trapman J, et al. (1994) Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Ann J Pathol 144: 735–746.
3. Pieta KJ, Bradley D (2006) Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 12: 1665–1671.
4. Nelson WG, De Marzo AM, Isaacs WB (2003) Prostate cancer. N Engl J Med 349: 369–381.
5. Ganswindt U, Stenzl A, Bamberg M, Belka C (2008) Adjuvant radiotherapy for localized prostate cancer and commonly persists in metastatic disease. Cancer 115152–15157.
6. Riedemann J, Sohail M, Macaulay VM (2007) Dual silencing of the EGFR and type 1 IGF receptors suggests dominance of IGF signaling in human breast cancer cells. Biochem Biophys Res Commun 355: 700–706.
7. Liu F, Wang J, You ZY, Zhang YD, Zhao Y (2010) Radiosensitivity of prostate cancer cells is enhanced by EGFR inhibitor C225. Urol Oncol 28: 39–66.
8. Liu Y, Majumder S, McCall W, Sartor CI, Mohler JL, et al. (2005) Inhibition of HER-2/new kinase impairs androgen receptor recruitment to the androgen responsive enhancer. Cancer Res 65: 3404–3409.
9. Barber PR, Locke R, Pierce GP, Rothkamm K, Vojnovic B (2007) Gamma-H2AX foci counting: image processing and control software for high-content screening. Proc SPIE 6441: 1–10.
10. Radziszewski E, Golub EI, Haaf T (1999) Nuclear foci of mammalian recombination proteins are located at single-stranded DNA regions formed after DNA damage. Proc Natl Acad Sci U S A 96: 1921–1926.
11. Sharma S, Raghavan SC (2010) Nonhomologous DNA end joining in cell-free extracts. J Nucleic Acids 2010.
12. Graham TR, Zhuo HE, Odero-Marah VA, Usosky OA, Kimbro KS, et al. (2008) Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res 68: 2479–2493.
13. Zhao HY, Zhang SM, Chen BQ, Wang Y, Zhang H, et al. (1996) Androgen-repressed phenotype in human prostate cancer. Proc Natl Acad Sci U S A 93: 15125–15137.
14. Yang S, Chintapalli J, Seedium L, Baskin S, Malhotra A, et al. (2005) Activated IGF-IR inhibits hyperglycemia-induced DNA damage and promotes DNA repair by homologous recombination. Am J Physiol Renal Physiol 290: F1144–1152.
15. Trojanek J, Ho T, Del Valle L, Nowicki M, Wang JY, et al. (2003) Role of the insulin-like growth factor I/insulin receptor substrate 1 axis in radioresistant and DNA repair by homologous recombination. Mol Cell Biol 23: 7510–7524.
16. Thomas J, Bristow KG (2010) DNA repair targeting and radiotherapy: a focus on the therapeutic ratio. Semin Radiat Oncol 20: 217–222.
17. Burton S, Chen BR, Chen DJ (2006) Role of non-homologous end joining (NHEJ) in maintaining genomic integrity. DNA Repair (Amst) 5: 1042–1048.
18. Deni P, Yacoub C, Contessa J, Caron R, Amoroso G, et al. (2003) Stress and radiation-induced activation of multiple intracellular signaling pathways. Radiat Res 159: 293–300.
28. Tokunaga E, Kataoka A, Kimura Y, Oki E, Mashino K, et al. (2006) The association between Akt activation and resistance to hormone therapy in metastatic breast cancer. Eur J Cancer 42: 629–635.

29. Kim TJ, Lee JW, Song SY, Choi JJ, Choi CH, et al. (2006) Increased expression of pAKT is associated with radiation resistance in cervical cancer. Br J Cancer 94: 1678–1682.